Genscript Biotech Corporation (G51) — Financial Flexibility Index
Genscript Biotech Corporation (G51) has a Financial Flexibility Index of -0.04x as of June 2023. Free cash flow of €-53.49 Million (operating CF €-93.58 Million minus capex €40.10 Million) represents 0% of total liabilities (€1.30 Billion). Also explore G51 net assets growth trend to track the company's year-over-year net asset growth rate.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Genscript Biotech Corporation Financial Flexibility Index (2016–2025)
Historical Financial Flexibility Index trend for Genscript Biotech Corporation across 10 annual periods. Check how strategically is Genscript Biotech Corporation's equity deployed to assess the company's strategic physical and investment asset allocation.
Annual Financial Flexibility Index for Genscript Biotech Corporation (2016–2025)
Year-by-year free cash flow to debt coverage for Genscript Biotech Corporation. For the full company profile including market capitalisation, see Genscript Biotech Corporation (G51) total market value.
| Year | Flexibility Index | Free Cash Flow (EUR) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.46x | €409.36 Million | €325.52 Million | €888.59 Million | ▲ +96.8% |
| 2024 | 0.23x | €223.57 Million | €75.65 Million | €954.91 Million | ▲ +343.4% |
| 2023 | -0.10x | €-129.20 Million | €-286.91 Million | €1.34 Billion | ▼ -236.7% |
| 2022 | 0.07x | €83.28 Million | €-120.29 Million | €1.18 Billion | ▲ +2240.7% |
| 2021 | 0.00x | €-3.75 Million | €-136.79 Million | €1.14 Billion | ▲ +92.9% |
| 2020 | -0.05x | €-29.21 Million | €-151.09 Million | €631.82 Million | ▼ -129.7% |
| 2019 | 0.16x | €80.42 Million | €-29.95 Million | €517.11 Million | ▼ -82.6% |
| 2018 | 0.89x | €378.50 Million | €307.66 Million | €423.68 Million | ▲ +387.4% |
| 2017 | 0.18x | €50.58 Million | €21.37 Million | €275.94 Million | ▼ -81.8% |
| 2016 | 1.01x | €42.26 Million | €33.27 Million | €42.01 Million | — |